Icerguastat

Icerguastat (Sephin1), a derivative of Guanabenz lacking the α2-adrenergic activity, is a selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A) . Icerguastat inhibits eIF2α dephosphorylation, thereby prolonging the protective response. Anti-prion effect[1][2][3].

Product Specifications

CAS Number

[951441-04-6]

Product Name Alternative

Sephin1; IFB-088

UNSPSC

12352005

Hazard Statement

H301

Target

Phosphatase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/icerguastat.html

Purity

99.93

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

ClC1=CC=CC=C1/C=N/NC(N)=N

Molecular Formula

C8H9ClN4

Molecular Weight

196.64

Precautions

H301

References & Citations

[1]Chen Y, et al. Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis. Brain. 2019;142 (2) :344-361.|[2]Das I, et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015;348 (6231) :239-242.|[3]Thapa S, et al. Sephin1 Reduces Prion Infection in Prion-Infected Cells and Animal Model. Mol Neurobiol. 2020;57 (5) :2206-2219.